JP2017527274A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017527274A5 JP2017527274A5 JP2017504103A JP2017504103A JP2017527274A5 JP 2017527274 A5 JP2017527274 A5 JP 2017527274A5 JP 2017504103 A JP2017504103 A JP 2017504103A JP 2017504103 A JP2017504103 A JP 2017504103A JP 2017527274 A5 JP2017527274 A5 JP 2017527274A5
- Authority
- JP
- Japan
- Prior art keywords
- binding molecule
- seq
- sequence
- bispecific binding
- light chain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108090000765 processed proteins & peptides Proteins 0.000 claims 31
- 102000004196 processed proteins & peptides Human genes 0.000 claims 20
- 230000004927 fusion Effects 0.000 claims 19
- 229920001184 polypeptide Polymers 0.000 claims 19
- 239000002157 polynucleotide Substances 0.000 claims 16
- 102000040430 polynucleotide Human genes 0.000 claims 16
- 108091033319 polynucleotide Proteins 0.000 claims 16
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 claims 15
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 claims 15
- 239000008194 pharmaceutical composition Substances 0.000 claims 15
- 206010028980 Neoplasm Diseases 0.000 claims 9
- 102000006496 Immunoglobulin Heavy Chains Human genes 0.000 claims 7
- 108010019476 Immunoglobulin Heavy Chains Proteins 0.000 claims 7
- 201000011510 cancer Diseases 0.000 claims 7
- 210000001744 T-lymphocyte Anatomy 0.000 claims 6
- 210000004027 cell Anatomy 0.000 claims 5
- 108060003951 Immunoglobulin Proteins 0.000 claims 4
- 102000018358 immunoglobulin Human genes 0.000 claims 4
- 239000000203 mixture Substances 0.000 claims 4
- 238000000034 method Methods 0.000 claims 3
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims 2
- 239000005551 L01XE03 - Erlotinib Substances 0.000 claims 2
- 239000002136 L01XE07 - Lapatinib Substances 0.000 claims 2
- 230000004988 N-glycosylation Effects 0.000 claims 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 2
- 229960005395 cetuximab Drugs 0.000 claims 2
- 229960001433 erlotinib Drugs 0.000 claims 2
- AAKJLRGGTJKAMG-UHFFFAOYSA-N erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 claims 2
- 239000012634 fragment Substances 0.000 claims 2
- 230000013595 glycosylation Effects 0.000 claims 2
- 238000006206 glycosylation reaction Methods 0.000 claims 2
- 229960004891 lapatinib Drugs 0.000 claims 2
- BCFGMOOMADDAQU-UHFFFAOYSA-N lapatinib Chemical compound O1C(CNCCS(=O)(=O)C)=CC=C1C1=CC=C(N=CN=C2NC=3C=C(Cl)C(OCC=4C=C(F)C=CC=4)=CC=3)C2=C1 BCFGMOOMADDAQU-UHFFFAOYSA-N 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 102000005962 receptors Human genes 0.000 claims 2
- 108020003175 receptors Proteins 0.000 claims 2
- 150000003384 small molecules Chemical class 0.000 claims 2
- 229960000575 trastuzumab Drugs 0.000 claims 2
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 201000009030 Carcinoma Diseases 0.000 claims 1
- 206010008342 Cervix carcinoma Diseases 0.000 claims 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 claims 1
- 208000006168 Ewing Sarcoma Diseases 0.000 claims 1
- 201000010915 Glioblastoma multiforme Diseases 0.000 claims 1
- 102000013463 Immunoglobulin Light Chains Human genes 0.000 claims 1
- 108010065825 Immunoglobulin Light Chains Proteins 0.000 claims 1
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 claims 1
- 206010029260 Neuroblastoma Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 229930012538 Paclitaxel Natural products 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 208000004337 Salivary Gland Neoplasms Diseases 0.000 claims 1
- 206010061934 Salivary gland cancer Diseases 0.000 claims 1
- 206010039491 Sarcoma Diseases 0.000 claims 1
- 208000021712 Soft tissue sarcoma Diseases 0.000 claims 1
- 208000000102 Squamous Cell Carcinoma of Head and Neck Diseases 0.000 claims 1
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 1
- 208000009956 adenocarcinoma Diseases 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 claims 1
- 190000008236 carboplatin Chemical compound 0.000 claims 1
- 229960004562 carboplatin Drugs 0.000 claims 1
- 230000001413 cellular effect Effects 0.000 claims 1
- 201000010881 cervical cancer Diseases 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 229960004397 cyclophosphamide Drugs 0.000 claims 1
- 229960003668 docetaxel Drugs 0.000 claims 1
- 229960004679 doxorubicin Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 230000003352 fibrogenic effect Effects 0.000 claims 1
- 206010017758 gastric cancer Diseases 0.000 claims 1
- 230000002496 gastric effect Effects 0.000 claims 1
- 201000007492 gastroesophageal junction adenocarcinoma Diseases 0.000 claims 1
- 208000005017 glioblastoma Diseases 0.000 claims 1
- 201000000459 head and neck squamous cell carcinoma Diseases 0.000 claims 1
- 238000007912 intraperitoneal administration Methods 0.000 claims 1
- 238000007913 intrathecal administration Methods 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 238000007914 intraventricular administration Methods 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 206010061289 metastatic neoplasm Diseases 0.000 claims 1
- 239000002773 nucleotide Substances 0.000 claims 1
- 125000003729 nucleotide group Chemical group 0.000 claims 1
- 201000008968 osteosarcoma Diseases 0.000 claims 1
- 229960001592 paclitaxel Drugs 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 201000009410 rhabdomyosarcoma Diseases 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 210000001519 tissue Anatomy 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462029342P | 2014-07-25 | 2014-07-25 | |
| US62/029,342 | 2014-07-25 | ||
| PCT/US2015/041989 WO2016014942A1 (en) | 2014-07-25 | 2015-07-24 | Bispecific her2 and cd3 binding molecules |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017527274A JP2017527274A (ja) | 2017-09-21 |
| JP2017527274A5 true JP2017527274A5 (index.php) | 2018-10-18 |
| JP6871155B2 JP6871155B2 (ja) | 2021-05-12 |
Family
ID=53836217
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017504103A Active JP6871155B2 (ja) | 2014-07-25 | 2015-07-24 | 二重特異性ｈｅｒ２及びｃｄ３結合分子 |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US10519248B2 (index.php) |
| EP (1) | EP3172236B1 (index.php) |
| JP (1) | JP6871155B2 (index.php) |
| KR (1) | KR102638104B1 (index.php) |
| CN (1) | CN107124884B (index.php) |
| AU (1) | AU2015292374B2 (index.php) |
| BR (1) | BR112017001513A2 (index.php) |
| CA (1) | CA2956014C (index.php) |
| ES (1) | ES2832704T3 (index.php) |
| IL (1) | IL250249B (index.php) |
| MX (1) | MX386342B (index.php) |
| RU (1) | RU2017105849A (index.php) |
| SG (1) | SG11201700506TA (index.php) |
| WO (1) | WO2016014942A1 (index.php) |
| ZA (1) | ZA201701341B (index.php) |
Families Citing this family (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HRP20240939T1 (hr) | 2013-12-17 | 2024-10-25 | Genentech, Inc. | Anti-cd3 protutijela i metode uporabe |
| CA2956014C (en) | 2014-07-25 | 2023-10-31 | Memorial Sloan Kettering Cancer Center | Bispecific her2 and cd3 binding molecules |
| US11820832B2 (en) | 2014-07-25 | 2023-11-21 | Memorial Sloan Kettering Cancer Center | Bispecific HER2 and CD3 binding molecules |
| EP3310811B1 (en) | 2015-06-16 | 2021-06-16 | Genentech, Inc. | Anti-cd3 antibodies and methods of use |
| CN109923128A (zh) | 2016-11-15 | 2019-06-21 | 基因泰克公司 | 用于用抗cd20/抗cd3双特异性抗体进行治疗的给药 |
| US11046768B2 (en) | 2017-01-27 | 2021-06-29 | Memorial Sloan Kettering Cancer Center | Bispecific HER2 and CD3 binding molecules |
| EP3574012A1 (en) * | 2017-01-27 | 2019-12-04 | Memorial Sloan Kettering Cancer Center | Bispecific her2 and cd3 binding molecules |
| US11529371B2 (en) | 2017-04-24 | 2022-12-20 | Memorial Sloan Kettering Cancer Center | Anti-CD33 antibody agents |
| CN107854490A (zh) * | 2017-09-26 | 2018-03-30 | 首都医科大学附属北京世纪坛医院 | 一种经修饰的t细胞及其应用 |
| EP3749361A1 (en) | 2018-02-08 | 2020-12-16 | F. Hoffmann-La Roche AG | Bispecific antigen-binding molecules and methods of use |
| US20210017295A1 (en) * | 2018-03-12 | 2021-01-21 | Memorial Sloan Kettering Cancer Center | Bispecific binding agents and uses thereof |
| CN111566127B (zh) * | 2018-03-27 | 2024-06-07 | 西雅图免疫公司 | 制导和导航控制蛋白及其制备和使用方法 |
| CN110357960A (zh) * | 2018-04-10 | 2019-10-22 | 广州爱思迈生物医药科技有限公司 | 抗体及抗体改造方法 |
| AR114284A1 (es) * | 2018-04-13 | 2020-08-12 | Hoffmann La Roche | Moléculas de unión a antígeno dirigidas a her2 que comprenden 4-1bbl |
| CA3103414A1 (en) | 2018-06-14 | 2019-12-19 | Bioatla, Inc. | Multi-specific antibody constructs |
| EP3889179A4 (en) * | 2018-11-01 | 2022-10-12 | Shandong New Time Pharmaceutical Co., Ltd. | Bispecific antibody and use thereof |
| CN111196856A (zh) * | 2018-11-19 | 2020-05-26 | 三生国健药业（上海）股份有限公司 | 抗her2/pd1双特异性抗体 |
| WO2020113164A1 (en) * | 2018-11-30 | 2020-06-04 | Memorial Sloan Kettering Cancer Center | Heterodimeric tetravalency and specificity antibody compositions and uses thereof |
| EP3894601A4 (en) * | 2018-12-11 | 2023-01-11 | The Translational Genomics Research Institute | IDENTIFICATION OF HER2 MUTATIONS IN LUNG CANCER AND METHODS OF TREATMENT |
| KR20210142628A (ko) * | 2019-02-22 | 2021-11-25 | 메모리얼 슬로안 케터링 캔서 센터 | Cd33 항체 및 이를 사용하여 암을 치료하는 방법 |
| WO2020210232A1 (en) * | 2019-04-08 | 2020-10-15 | Memorial Sloan Kettering Cancer Center | Cd19 antibodies and methods of using the same |
| JOP20210298A1 (ar) | 2019-05-14 | 2023-01-30 | Provention Bio Inc | طرق وتركيبات للوقاية من مرض السكري من النوع الأول |
| CA3139111A1 (en) * | 2019-05-23 | 2020-11-26 | VelosBio Inc. | Anti-ror1/anti-cd3 bispecific binding molecules |
| CN114401744B (zh) * | 2019-06-26 | 2024-11-05 | 纪念斯隆凯特琳癌症中心 | 用于治疗癌症的抗cd33抗体 |
| KR20220113790A (ko) | 2019-12-13 | 2022-08-16 | 제넨테크, 인크. | 항-ly6g6d 항체 및 사용 방법 |
| WO2021252917A2 (en) | 2020-06-11 | 2021-12-16 | Provention Bio, Inc. | Methods and compositions for preventing type 1 diabetes |
| WO2022026439A2 (en) * | 2020-07-28 | 2022-02-03 | Memorial Sloan Kettering Cancer Center | Compositions including ex vivo armed t cells with multi-specific antibodies and uses thereof |
| US20230374150A1 (en) * | 2020-10-12 | 2023-11-23 | Memorial Sloan Kettering Cancer Center | Anti-psma antibodies and uses thereof |
| IL302217A (en) | 2020-11-04 | 2023-06-01 | Genentech Inc | Dosage for treatment with bispecific anti-CD20/anti-CD3 antibodies and anti-CD79B drug antibody conjugates |
| CA3196076A1 (en) | 2020-11-04 | 2022-05-12 | Chi-Chung Li | Subcutaneous dosing of anti-cd20/anti-cd3 bispecific antibodies |
| EP4240492A2 (en) | 2020-11-04 | 2023-09-13 | Genentech, Inc. | Dosing for treatment with anti-cd20/anti-cd3 bispecific antibodies |
| US11661459B2 (en) | 2020-12-03 | 2023-05-30 | Century Therapeutics, Inc. | Artificial cell death polypeptide for chimeric antigen receptor and uses thereof |
| EP4255922A1 (en) | 2020-12-03 | 2023-10-11 | Century Therapeutics, Inc. | Genetically engineered cells and uses thereof |
| WO2022133169A1 (en) | 2020-12-18 | 2022-06-23 | Century Therapeutics, Inc. | Chimeric antigen receptor systems with adaptable receptor specificity |
| AU2022273541A1 (en) | 2021-05-14 | 2023-11-30 | Genentech, Inc. | Methods for treatment of cd20-positive proliferative disorder with mosunetuzumab and polatuzumab vedotin |
| CA3228259A1 (en) * | 2021-08-04 | 2023-02-09 | Abpro Corporation | Anti-her2 antibodies and uses thereof |
| EP4419567A4 (en) * | 2021-10-20 | 2025-09-17 | Memorial Sloan Kettering Cancer Center | MULTI-SPECIFIC ANTI-TSHR ANTIBODIES AND THEIR USES |
| KR102803655B1 (ko) | 2021-12-29 | 2025-05-08 | 건국대학교 글로컬산학협력단 | 개과 동물의 her1 및 cd3에 특이적으로 결합하는 이중특이적 항체 및 이의 용도 |
| KR102857671B1 (ko) | 2021-12-29 | 2025-09-10 | 건국대학교 글로컬산학협력단 | 개과 동물의 her2 및 cd3에 특이적으로 결합하는 이중특이적 항체 및 이의 용도 |
| TWI874962B (zh) | 2022-04-13 | 2025-03-01 | 美商建南德克公司 | 莫蘇妥珠單抗之醫藥組成物及其使用方法 |
| AU2024214000A1 (en) * | 2023-02-04 | 2025-08-21 | Imagion Biosystems, Inc. | Method to assess nodal disease using iron oxide nanoparticles in magnetic resonance imaging |
| WO2025076473A1 (en) * | 2023-10-06 | 2025-04-10 | Fred Hutchinson Cancer Center | Proteins bispecific to cd3 and nkg2dl and associated uses thereof |
| WO2025085781A1 (en) | 2023-10-19 | 2025-04-24 | Genentech, Inc. | Combinations of il15/il15r alpha heterodimeric fc-fusion proteins and her2xcd3 bispecific antibodies for the treatment of her2-positive cancers |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5885573A (en) * | 1993-06-01 | 1999-03-23 | Arch Development Corporation | Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies |
| JP5139800B2 (ja) | 2004-06-03 | 2013-02-06 | ノビミューン エスアー | 抗ｃｄ３抗体およびその使用方法 |
| FI2155783T4 (fi) | 2007-04-03 | 2022-12-15 | Lajien välisesti spesifinen cd3-epsilon-sitoutumisdomeeni | |
| US8648176B2 (en) | 2009-02-27 | 2014-02-11 | Massachusetts Institute Of Technology | Engineered proteins with high affinity for DOTA chelates |
| JP6320753B2 (ja) | 2010-05-27 | 2018-05-09 | ゲンマブ エー／エス | Ｈｅｒ２に対するモノクローナル抗体 |
| US9315585B2 (en) * | 2010-06-19 | 2016-04-19 | Memorial Sloan Kettering Cancer Center | Anti-GD2 antibodies |
| WO2012143524A2 (en) | 2011-04-20 | 2012-10-26 | Genmab A/S | Bispecific antibodies against her2 and cd3 |
| SG194875A1 (en) * | 2011-05-08 | 2013-12-30 | Legochem Biosciences Inc | Protein-active agent conjugates and method for preparing the same |
| US11492383B2 (en) | 2011-06-24 | 2022-11-08 | Stephen D. Gillies | Light chain immunoglobulin fusion proteins and methods of use thereof |
| JP6020581B2 (ja) * | 2011-11-02 | 2016-11-02 | 味の素株式会社 | タンパク質の分泌生産法 |
| EP2895203A4 (en) * | 2012-06-15 | 2016-09-28 | Imaginab Inc | ANTIGENBINDING CONSTRUCTS FOR CD3 |
| WO2014079000A1 (en) | 2012-11-21 | 2014-05-30 | Wuhan Yzy Biopharma Co., Ltd. | Bispecific antibody |
| DK3024851T3 (en) * | 2013-07-25 | 2018-08-06 | Cytomx Therapeutics Inc | MULTI-SPECIFIC ANTIBODIES, MULTI-SPECIFICALLY ACTIVABLE ANTIBODIES, AND METHODS FOR USING IT |
| CN112353943A (zh) | 2013-12-17 | 2021-02-12 | 豪夫迈·罗氏有限公司 | 用pd-1轴结合拮抗剂和紫杉烷治疗癌症的方法 |
| CA2956014C (en) | 2014-07-25 | 2023-10-31 | Memorial Sloan Kettering Cancer Center | Bispecific her2 and cd3 binding molecules |
| CA2976074A1 (en) | 2015-02-09 | 2016-08-18 | Memorial Sloan Kettering Cancer Center | Multi-specific antibodies with affinity for human a33 antigen and dota metal complex and uses thereof |
| US11046768B2 (en) | 2017-01-27 | 2021-06-29 | Memorial Sloan Kettering Cancer Center | Bispecific HER2 and CD3 binding molecules |
| EP3574012A1 (en) | 2017-01-27 | 2019-12-04 | Memorial Sloan Kettering Cancer Center | Bispecific her2 and cd3 binding molecules |
-
2015
- 2015-07-24 CA CA2956014A patent/CA2956014C/en active Active
- 2015-07-24 KR KR1020177004024A patent/KR102638104B1/ko active Active
- 2015-07-24 JP JP2017504103A patent/JP6871155B2/ja active Active
- 2015-07-24 EP EP15750184.2A patent/EP3172236B1/en active Active
- 2015-07-24 SG SG11201700506TA patent/SG11201700506TA/en unknown
- 2015-07-24 AU AU2015292374A patent/AU2015292374B2/en active Active
- 2015-07-24 US US15/328,288 patent/US10519248B2/en active Active
- 2015-07-24 MX MX2017001031A patent/MX386342B/es unknown
- 2015-07-24 ES ES15750184T patent/ES2832704T3/es active Active
- 2015-07-24 BR BR112017001513-7A patent/BR112017001513A2/pt not_active Application Discontinuation
- 2015-07-24 RU RU2017105849A patent/RU2017105849A/ru not_active Application Discontinuation
- 2015-07-24 CN CN201580051950.XA patent/CN107124884B/zh active Active
- 2015-07-24 WO PCT/US2015/041989 patent/WO2016014942A1/en not_active Ceased
-
2017
- 2017-01-23 IL IL250249A patent/IL250249B/en active IP Right Grant
- 2017-02-22 ZA ZA2017/01341A patent/ZA201701341B/en unknown
-
2019
- 2019-12-13 US US16/714,636 patent/US11987642B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017527274A5 (index.php) | ||
| RU2017105849A (ru) | Биспецифические молекулы, связывающие her2 и cd3 | |
| Ma et al. | Bispecific antibodies: from research to clinical application | |
| Fan et al. | Bispecific antibodies and their applications | |
| JP2020063262A5 (index.php) | ||
| Marvin et al. | Recombinant approaches to IgG‐like bispecific antibodies | |
| JP2017520575A5 (index.php) | ||
| JP2019524693A5 (index.php) | ||
| JP2013527761A5 (index.php) | ||
| FI3749346T3 (fi) | Nkg2d-reseptoriin kohdistuvat vasta-aineen vaihtelevan domeenin yhdistelmät | |
| JP2020533311A5 (ja) | ＮＫＧ２Ｄ、ＣＤ１６およびＮｅｃｔｉｎ４に結合するタンパク質 | |
| JP2017504578A5 (index.php) | ||
| JP2020531438A5 (ja) | Ｎｋｇ２ｄ、ｃｄ１６、およびｈｌａ−ｅに結合するタンパク質 | |
| JP2018503380A5 (index.php) | ||
| JP2018507188A5 (index.php) | ||
| RU2021110369A (ru) | Белки, связывающие nkg2d, cd16 и опухолеассоциированный антиген | |
| WO2013044215A4 (en) | Vegf/dll4 binding agents and uses thereof | |
| RU2016151645A (ru) | Биспецифические гетеродимерные диантитела и их применение | |
| RU2022102446A (ru) | Биспецифические связывающие белки и пути их применения | |
| HRP20200390T1 (hr) | Monoklonska antitijela protiv humanog antigena starenja b stanica (bcma) | |
| JP2019500011A5 (index.php) | ||
| IL295295A (en) | Antibodies targeting fc receptor-like 5 and methods of use | |
| WO2018119118A4 (en) | Lymphotoxin-beta receptor-binding agents, targeting antibodies, and uses thereof | |
| JP2012519492A5 (index.php) | ||
| RU2016136527A (ru) | Улучшенные способы лечения васкуляризированных злокачественных опухолей |